Cyclophosphamide versus placebo in scleroderma lung disease.

By D. Tashkin, R. Elashoff, Philip J. Clements, J. Goldin, Michael D. Roth, D. Furst, E. Arriola, R. Silver, C. Strange, M. Bolster and 21 more. New England Journal of Medicine, 2006

1,467 citations recorded by the source corpus.

Subfields: Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/84671683d7b36e019f937e08d1a9e4763f37127c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Wells
2. N. Hirani
3. N. Goh
4. R. D. du Bois
5. S. Desai
6. S. Veeraraghavan
7. D. Hansell
8. C. Black

Citations in the corpus

• Interstitial lung disease guideline (2008, background): “53% higher than the placebo group after 1 year of treatment.(516) Corticosteroid use was at the discretion of the attending”
• Interstitial lung disease in systemic sclerosis: a simple staging system. (2008, background): “Second, in the recent scleroderma lung studies ( 16 , 17), an FVC level of 70% was the threshold below which therapy was effective in preventing disease progression, an effect that was lost with the cessation of treatment.”